The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

Antonio Jimeno, MD, PhD, led research studying a cell squeezing process used to treat a subtype of HPV16-driven head and neck cancer.

Experts stress the need for targeted efforts to increase vaccine uptake among cancer patients with lower vaccination rates.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

Risk-based testing alone has failed to identify a majority of people living with chronic HBV.

A small group of adults in remission had persisting mutations that predicted their risk of death from having the cancer return.

Dana-Farber researchers explore CAR-T therapy and next generation immunotherapy to target colorectal cancer.

Fred Hutch study suggests certain immune cells are the source of antibodies that attack donated organs.

Women with lymphoma who received treatment in the afternoon had lower relapse and mortality rates than those treated earlier in the day.